top of page

mimiX biotherapeutics launches a funding round to accelerate clinical translation of FastSkin®

Biel, Switzerland, 19 December 2022 – MIMIX BIOTHERAPEUTICS LTD, a Swiss

medical technology company focused on life sciences, with a next-generation 3D

bioprinting platform using proprietary Sound Induced Morphogenesis (SIM),

announces that the company is accelerating the clinical translation of FastSkin®.


FastSkin® is an advanced dermal substitute for acute and chronic wound

treatment. It creates new therapeutic opportunities in the treatment of complex

wounds, a major social burden and clinical unmet need in skin cancer, acute and

chronic wounds.


«FastSkin® is a major advance in personalized regenerative medicine, opening

the door to new treatment options while increasing patient accessibility” stated

Marc Thurner, mimiX biotherapeutics Chairman and CEO.


The global skin cancer market is projected to reach USD 14.55bn by 2027. The

increase in diabetes, obesity & chronic conditions is expected to augment the

demand for advanced wound care products, a market estimated to USD 24bn by

2030*.


The company is launching a funding round in January 2023 to accelerate U.S.

market clearance and market launch.


*Source: 2017, Advanced wound care market, Markets and Markets; Alira Health analysis.


mimiX bio launches FastSkin- Press release
.pdf
Download PDF • 118KB


About mimiX biotherapeutics Ltd.

Established in 2019, the company leverages Sound Induced Morphogenesis (SIM),

a proprietary technology that uses sound in conjunction with cells, stem cells,

spheroids, organoids & bioactives, to create tissue relevant architectures (biopatterns).


SIM replicates natures’ design strategy by controlling shape & function,

the two fundamentals in developmental biology.

Sound Induced Morphogenesis was developed as a result of 10+ years of research

and development efforts incubated at the AO Foundation

in Davos, Switzerland.


Headquartered at the Switzerland Innovation Park in Biel, the company has

embedded its base SIM technology into cymatiX®, a discovery platform for a large

range of applications, from life sciences to drug development, cellular agriculture

and performance materials.


Previous financing rounds have brought on board investors such as Heraeus and AO Foundation , as well as private investors.


Press contact

Communication & media: roman.sojic@mimixbio.com

Phone: +41 78 801 74 10

mimiX biotherapeutics Ltd, Aarbergstrasse 46, 2503 Biel, Switzerland

Comments


bottom of page